The operational turnaround is real but fragile — the company is burning cash and has thin liquidity ($289K cash vs. $10.8M short-term loans). Monitor the next 10-Q for cash flow trends and accounts receivable collection. The active shelf registrations (F-3 and F-1) signal potential equity dilution ahead, which could cap upside. The prior 20-F's material weakness finding remains unresolved.
Price Chart
Executive Summary
Baird Medical reported preliminary unaudited H1 2026 results with revenue of $9.9M (+24.6% YoY) and a swing to positive net income of ~$14K from a -$11.4M loss in H1 2025. The improvement was driven by a 32% gross profit increase, 87% gross margin, and a sharp reduction in operating expenses (R&D and G&A down ~80% combined). However, cash dropped to $289K from $566K at year-end 2025, and accounts receivable remain high at $30.7M, raising liquidity concerns for a $47M market cap company. The prior 20-F (132 days ago) flagged a 39% revenue decline in 2025 and material weaknesses — this H1 reversal is a notable operational turnaround but on a small base and unaudited.
Key Facts
- Revenue for H1 2026 was $9.9M, up 24.6% from $8.0M in H1 2025.
- Net income was ~$14,000 vs. a net loss of $(11.4)M in H1 2025.
- Gross margin improved to 87.0% from 82.1% in the prior-year period.
- Operating expenses fell to $7.8M from $17.0M, driven by R&D and G&A cuts.
- Cash and restricted cash declined to $289K from $566K at Dec 31, 2025.
- Accounts receivable remained elevated at $30.7M, representing ~3x H1 revenue.
- Adjusted EBITDA was $4.0M vs. $(3.3)M in H1 2025.
- U.S. revenue contributed ~27% of H1 2026 revenue vs. <2% in H1 2025.
- The company has active shelf registration statements on Form F-3 and F-1.
- Prior 20-F (April 2026) reported a 39% revenue decline for FY2025 and material weaknesses in internal controls.
Financial Impact
Revenue growth of $1.96M (+24.6%) and swing from -$11.4M net loss to +$14K net income; cash burn of ~$277K in 6 months; accounts receivable at $30.7M vs. $9.9M revenue
Risk Factors
- Cash position of $289K is critically low relative to $10.8M in short-term loans and $3.3M in current portion of long-term debt
- Accounts receivable of $30.7M is 3.1x H1 revenue, suggesting collection risk or aggressive revenue recognition
- Results are preliminary and unaudited, subject to year-end adjustment
- Active shelf registrations (F-3 and F-1) create potential for dilutive equity offerings
- Prior material weakness in internal controls over financial reporting (from 20-F) remains unresolved
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-104934 |
| Document: tm2624742d1_6k.htm | 0001104659-26-104934 |
| Document: 0001104659-26-104934-index-headers.html | 0001104659-26-104934 |
| Document: 0001104659-26-104934-index.html | 0001104659-26-104934 |
| Document: 0001104659-26-104934.txt | 0001104659-26-104934 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 6-K | $0.7440 | awaiting T+20 | — | $0.4277 (+42.51%) |
Sep 30, 2026 26d ago | 6-K | $0.7800 | awaiting T+20 | — | $0.4277 (−45.17%) |
Sep 3, 2026 7w ago | 6-K | $1.17 $0.7511 | ▼ −35.80% | ▼ −34.62% | $0.4277 (−63.44%) |
Sep 3, 2026 7w ago | Press Release | $1.17 $0.7511 | ▼ −35.80% | ▼ −34.62% | $0.4277 (−63.44%) |
Aug 18, 2026 9w ago | EFFECT | $1.09 $1.06 | ▲ +2.75% | ▲ +1.76% | $0.4277 (+60.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers